微生物游离DNA测序作为新生儿败血症传统诊断方法的补充手段。
Microbial cell-free DNA-sequencing as an addition to conventional diagnostics in neonatal sepsis.
作者信息
Balks Julian, Grumaz Silke, Mazzitelli Sonia, Neder Ulrike, Lemloh Lotte, Melaku Tamene, Glaser Kirsten, Mueller Andreas, Kipfmueller Florian
机构信息
Division of Neonatology and Pediatric Intensive Care, Children's Hospital, University of Bonn, Bonn, Germany.
Institute of Medical Microbiology, Immunology and Parasitology (IMMIP), University Hospital Bonn, Bonn, Germany.
出版信息
Pediatr Res. 2025 Feb;97(2):614-624. doi: 10.1038/s41390-024-03448-1. Epub 2024 Aug 14.
BACKGROUND
Bloodstream infections remain a challenge for neonatologists, as traditional culture-based methods are time-consuming and rely on adequate blood volume. Next-generation sequencing (NGS) offers an alternative, as it can identify microbial cell-free DNA (mcfDNA) in a small blood sample, providing rapid pathogen detection. This study aimed to assess the diagnostic performance of DISQVER®-NGS compared to blood cultures in neonatal patients with suspected sepsis.
METHODS
In neonates with suspected sepsis, blood cultures and samples for NGS were prospectively collected. Patients were divided into four categories: 1) sepsis, blood culture positive, 2) clinical sepsis, culture negative, 3) suspected sepsis, 4) validation cohort.
RESULTS
NGS detected bacterial, viral or fungal mcfDNA in 24 of 82 samples. Blood cultures were collected in 46 of 84 patients (15/46 positive). DISQVER® correctly identified pathogens in 9/15 patients with a positive blood culture, two with intrinsic resistance to their antibiotic regimen. In seven samples NGS reported the mcfDNA of bacteria that could have theoretically grown in culture but did not.
CONCLUSIONS
NGS may enhance sensitivity in sepsis diagnostics by detecting mcfDNA in neonates with suspected sepsis. Interpreting NGS results requires correlation with clinical data, laboratory values, and routine microbiological tests for a comprehensive understanding of the patient's condition.
IMPACT
Conventional blood culture methods have limitations in accuracy and turnaround time. The study aimed to investigate the diagnostic performance of the Next-Generation Sequencing method DISQVER® compared to traditional blood cultures in neonatal patients with suspected sepsis. Our findings suggest that NGS has the potential to augment the precision of conventional diagnostic techniques, can lead to improved detection of pathogens and targeted treatment approaches in neonatal sepsis. It is emphasized that further validation and integration with clinical and microbiological data are required to ensure optimal clinical utility.
背景
血流感染仍是新生儿科医生面临的一项挑战,因为传统的基于培养的方法耗时且依赖足够的血量。新一代测序(NGS)提供了一种替代方法,因为它可以在少量血样中识别微生物游离DNA(mcfDNA),从而实现病原体的快速检测。本研究旨在评估DISQVER®-NGS相对于血培养在疑似脓毒症新生儿患者中的诊断性能。
方法
前瞻性收集疑似脓毒症新生儿的血培养样本和用于NGS的样本。患者分为四类:1)脓毒症,血培养阳性;2)临床脓毒症,培养阴性;3)疑似脓毒症;4)验证队列。
结果
在82份样本中的24份中检测到细菌、病毒或真菌的mcfDNA。84例患者中的46例进行了血培养(15/46阳性)。DISQVER®在9/15血培养阳性的患者中正确识别出病原体,其中2例对其抗生素治疗方案具有内在抗性。在7份样本中,NGS报告了理论上可在培养中生长但未生长的细菌的mcfDNA。
结论
NGS可通过检测疑似脓毒症新生儿的mcfDNA提高脓毒症诊断的敏感性。解读NGS结果需要与临床数据、实验室值和常规微生物检测相关联,以便全面了解患者病情。
影响
传统血培养方法在准确性和周转时间方面存在局限性。本研究旨在调查新一代测序方法DISQVER®相对于传统血培养在疑似脓毒症新生儿患者中的诊断性能。我们的研究结果表明,NGS有可能提高传统诊断技术的精度,可改善新生儿脓毒症病原体的检测和靶向治疗方法。需要强调的是,为确保最佳临床效用,需要进一步验证并与临床和微生物数据整合。